Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
COF009
- Development stage
- Preclinical
- Lead developer
- Lee's Pharmaceutical Holdings
- Modality
- Small Molecules
01
Overview
COF009 is a small molecule inhibitor of hematopoietic progenitor kinase 1 (HPK1) currently in preclinical development by Lee's Pharmaceutical and its subsidiary ZKGZ Biotech (Zhaoke Guangzhou). HPK1 is a member of the MAP4K family and functions as a negative regulator of T-cell receptor (TCR) signaling. By inhibiting HPK1, COF009 is designed to augment T-cell activation and proliferation, thereby reversing immunosuppression in the tumor microenvironment and enhancing the immune system's ability to recognize and destroy tumor cells. The drug is being evaluated for the treatment of various solid tumors as a potential immuno-oncology therapy.
02
Targets
MAP4K1 (Hematopoietic progenitor kinase 1)
Beyond the preview
Go deeper on COF009.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on COF009.